Key result
Recombinant Norovirus 3Dpol synthesized RNA in vitro via de novo initiation and displayed terminal transferase activity, enabling the development of in vitro assays for antiviral drug validation.
Population
Recombinant Norovirus (NV) 3D(pol) and a 3D(pol) active-site mutant expressed in Escherichia coli
Design
Preclinical
Authors
Loading...
May aid norovirus antiviral screening; leaves open clinical translation from in vitro assays.
Characterization of NV 3D(pol) in vitro establishes an enzymic assay that can be used for the development and validation of antiviral drugs against norovirus.
Rohayem et al. (2006) studied Norovirus. Recombinant NV 3D(pol) vs. 3D(pol) active-site mutant was evaluated on RNA synthesis and terminal transferase activity. Recombinant Norovirus 3Dpol synthesized RNA in vitro via de novo initiation and displayed terminal transferase activity, enabling the development of in vitro assays for antiviral drug validation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: